
Insights Into Differentiated Thyroid Cancer (DTC) 2024
Perspectives on the management of radioactive iodine (RAI)-refractory or -ineligible metastatic DTC and second-line systemic therapy
Faculty Chair
Marcia Brose, MD, PhD
Sidney Kimmel Cancer Center, Philadelphia, PA, USA
More Information
- Virtual series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
REPORT SNAPSHOT
- Management of RAI-Refractory or -Ineligible Metastatic DTC
- Second-Line Systemic Therapy
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and in-depth moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region